Your browser doesn't support javascript.
loading
Humoral immune response and safety of SARS-CoV-2 vaccination in very early onset inflammatory bowel disease.
Kastl, Arthur J; Weaver, Kimberly N; Zhang, Xian; Strople, Jennifer A; Adler, Jeremy; Kelsen, Judith R; Dubinsky, Marla C; Bousvaros, Athos; Watkins, Runa; Dai, Colin; Cross, Raymond K; Higgins, Peter D R; Ungaro, Ryan; Bewtra, Meenakshi; Bellaguarda, Emanuelle A; Farraye, Francis A; Chun, Kelly; Zikry, Michael; Bastidas, Monique; Boccieri, Margie E; Firestine, Ann; Long, Millie D; Kappelman, Michael D.
Afiliação
  • Kastl AJ; Division of Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Weaver KN; Department of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Zhang X; Department of Pediatrics, Division of Pediatric Gastroenterology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Strople JA; Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
  • Adler J; Susan B. Meister Child Health Evaluation and Research Center and Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA.
  • Kelsen JR; Division of Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Dubinsky MC; Department of Pediatrics, Susan and Leonard Feinstein IBD Center, Icahn School of Medicine, Mount Sinai, New York, USA.
  • Bousvaros A; Children's Hospital, Boston, Massachusetts, USA.
  • Watkins R; Division of Pediatric Gastroenterology and Nutrition, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Dai C; Department of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Cross RK; Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Higgins PDR; Department of Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
  • Ungaro R; Department of Medicine, Susan and Leonard Feinstein IBD Center, Icahn School of Medicine, Mount Sinai, New York, USA.
  • Bewtra M; Department of Medicine, Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Bellaguarda EA; Division of Gastroenterology and Hepatology, Northwestern University, Chicago, Illinois, USA.
  • Farraye FA; Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA.
  • Chun K; Esoterix Specialty Laboratory, LabCorp, Calabasas, California, USA.
  • Zikry M; Esoterix Specialty Laboratory, LabCorp, Calabasas, California, USA.
  • Bastidas M; Esoterix Specialty Laboratory, LabCorp, Calabasas, California, USA.
  • Boccieri ME; Department of Pediatrics, Division of Pediatric Gastroenterology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Firestine A; Department of Pediatrics, Division of Pediatric Gastroenterology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Long MD; Department of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Kappelman MD; Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
J Pediatr Gastroenterol Nutr ; 78(4): 871-877, 2024 Apr.
Article em En | MEDLINE | ID: mdl-38356293
ABSTRACT
Children with very early onset inflammatory bowel disease (VEO-IBD) may respond differently to coronavirus disease 2019 (COVID-19) immunization compared to healthy children or other patients with IBD. We recruited children with VEO-IBD <6 years of age and younger following receipt of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. Demographics, IBD characteristics, medication use, adverse events (AEs) and IBD exacerbations were collected. Blood draws (optional) were obtained for measurement of antireceptor binding domain (RBD) IgG antibodies following vaccination. Of 41 participants, none required emergency department visit or hospitalization due to AE, and only one experienced IBD exacerbation. Detectable antibody was present in 19/19 participants who provided blood sample; 6/7 participants (86%) had durable humoral response 12 months postvaccination. Children with VEO-IBD experience robust humoral immune response to COVID-19 immunization. Severe AEs were rare. These findings provide reassurance that children with VEO-IBD respond well and safely to SARS-CoV-2 vaccination.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Inflamatórias Intestinais / COVID-19 Limite: Child / Humans Idioma: En Revista: J Pediatr Gastroenterol Nutr Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Inflamatórias Intestinais / COVID-19 Limite: Child / Humans Idioma: En Revista: J Pediatr Gastroenterol Nutr Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos